As the deadline draws near, the organizations that will succeed under DSCSA are those that understand compliance is not a ...

CMS announced a 44% net savings on 15 high-cost drugs under Medicare, effective January 2027, as part of the Inflation ...

In today’s Pharma Pulse, the federal government prepares to unveil newly negotiated Medicare prices for 15 high-cost drugs, ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to enhance financial flexibility and ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

Manufacturers now face a rapidly evolving landscape where tariffs can shift overnight—from metals to paper to other key ...

A new Pharma Pulse briefing unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III ...

Abbott's deal shakes up cancer diagnostics, new research confirms pandemic fatigue's impact on public compliance, and more in today’s Pharma Pulse.

Although CNPVs are widely viewed as a valuable opportunity, the criteria for selection remain somewhat opaque. One of the program’s stated goals is to bolster domestic drug production, particularly ...

AstraZeneca's $2 billion investment in Maryland will expand biologics manufacturing and establish a new clinical-stage ...

In final part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, points out how ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...